| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00008571-200406000-00002 |
| P698 | PubMed publication ID | 15247625 |
| P50 | author | Munir Pirmohamed | Q20127995 |
| Dyfrig A. Hughes | Q40943753 | ||
| P2093 | author name string | B Kevin Park | |
| Ana Alfirevic | |||
| F Javier Vilar | |||
| Charlotte C Ward | |||
| P433 | issue | 6 | |
| P921 | main subject | abacavir | Q304330 |
| cost-effectiveness analysis | Q1754768 | ||
| P304 | page(s) | 335-342 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity | |
| P478 | volume | 14 |
| Q35023821 | A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno |
| Q38777644 | A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions. |
| Q37095697 | Abacavir hypersensitivity reaction: an update |
| Q37803527 | Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles |
| Q38663764 | Advances in the Pharmacogenomics of Adverse Drug Reactions. |
| Q57302751 | Adverse drug reactions and pharmacogenomics: recent advances |
| Q36081993 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics |
| Q34075812 | Antiviral drug allergy. |
| Q46445488 | Applicability of pharmacogenetic studies in daily clinical practice |
| Q26783472 | Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine |
| Q49612005 | Benefit of pre-emptive pharmacogenetic information on clinical outcome. |
| Q47928481 | Biomarkers of adverse drug reactions. |
| Q36596713 | Can pharmacogenetics help rescue drugs withdrawn from the market? |
| Q34081675 | Cardiac biomarkers in HIV-exposed uninfected children |
| Q50654749 | Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. |
| Q88790405 | Challenges and opportunities of pharmacogenetics in drug development |
| Q36029478 | Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing |
| Q40381501 | Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele |
| Q37799352 | Cost effectiveness of pharmacogenomics: a critical and systematic review. |
| Q42243458 | Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany |
| Q28072203 | Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany |
| Q41676984 | Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment |
| Q38671676 | Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? |
| Q90859692 | Cross-ethnicity tagging SNPs for HLA alleles associated with adverse drug reaction |
| Q42132518 | Cutaneous drug hypersensitivity: immunological and genetic perspective |
| Q35586019 | Development and implementation of a pharmacist-managed clinical pharmacogenetics service. |
| Q38222509 | Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q40218681 | Drug hypersensitivity reactions in patients with HIV disease |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q39887958 | Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future |
| Q47334709 | Drugs for rare disorders |
| Q38904691 | Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality |
| Q35890606 | Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature |
| Q42665272 | Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. |
| Q93080606 | Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials |
| Q36659874 | Expressed sequence tags (ESTs) and single nucleotide polymorphisms (SNPs): what large-scale sequencing projects can tell us about ADME. |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q52660415 | Frank Stinchfield Award: Identification of the At-risk Genotype for Development of Pseudotumors Around Metal-on-metal THAs. |
| Q52588359 | Genetic Testing in Clinical Settings. |
| Q37389496 | Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example |
| Q34508545 | Genetic factors in the predisposition to drug-induced hypersensitivity reactions |
| Q84407710 | Genetic susceptibility in sepsis: implications for the pediatric population |
| Q36580332 | Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? |
| Q24202114 | Genetic testing for prevention of severe drug-induced skin rash |
| Q34072196 | Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q34566776 | HLA-B locus in Caucasian patients with carbamazepine hypersensitivity |
| Q46445494 | HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance |
| Q33768961 | HLA-B*5701 testing to predict abacavir hypersensitivity |
| Q47826173 | HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q34976463 | Hypersensitivity reactions to HIV therapy |
| Q36546268 | Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy |
| Q57610568 | Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan |
| Q36017113 | Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases |
| Q57302639 | Mechanisms of Adverse Drug Reactions |
| Q26744637 | MinION: A Novel Tool for Predicting Drug Hypersensitivity? |
| Q44357874 | NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q36885640 | Nucleoside and nucleotide reverse transcriptase inhibitors in children |
| Q36690248 | Overview of the pharmacoeconomics of pharmacogenetics |
| Q36389312 | Overview of the pharmacogenetics of HIV therapy. |
| Q36412674 | Personalized medicine: decades away? |
| Q33819062 | PharmGKB summary: abacavir pathway |
| Q35168561 | PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. |
| Q37194753 | Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines |
| Q97883055 | Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions |
| Q37120841 | Pharmacogenetic information derived from analysis of HLA alleles |
| Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
| Q37151528 | Pharmacogenetic testing: Current Evidence of Clinical Utility |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q26797938 | Pharmacogenetics as a tool to tailor antiretroviral therapy: A review |
| Q35172002 | Pharmacogenetics in Ghana: reviewing the evidence |
| Q34499056 | Pharmacogenetics in clinical practice: considerations for testing |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q57302676 | Pharmacogenetics of Adverse Drug Reactions |
| Q37107177 | Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility |
| Q37251569 | Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy |
| Q60486854 | Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? |
| Q31144283 | Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q36341730 | Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again |
| Q37077485 | Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients |
| Q37082500 | Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues |
| Q44631942 | Prospective validation of a pharmacogenetic test: the PREDICT-1 study |
| Q50071892 | Rare disease prevention and treatment: the need for a level playing field. |
| Q58006174 | Reacciones de hipersensibilidad a antirretrovirales en pacientes con infección por el virus de la inmunodeficiencia humana |
| Q38941642 | Role of pharmacogenetics in public health and clinical health care: a SWOT analysis |
| Q36989859 | Routine pharmacogenetic testing in clinical practice: dream or reality? |
| Q28076600 | Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation |
| Q38080040 | Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine |
| Q37436365 | Successful translation of pharmacogenetics into the clinic: the abacavir example |
| Q34623044 | Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. |
| Q37814401 | Systematic review of pharmacoeconomic studies of pharmacogenomic tests |
| Q45958696 | TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. |
| Q53251394 | The 2nd International Drug Hypersensitivity Meeting 18 - 21 April 2006, The University of Liverpool, Liverpool, UK. |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q38064446 | The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods |
| Q36497078 | The clinical implications of antiretroviral pharmacogenomics |
| Q37111658 | The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. |
| Q59352293 | The dawn of precision medicine in HIV: state of the art of pharmacotherapy |
| Q42010168 | Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. |
| Q36149081 | Understanding genomics: implications for the emergency medicine physician and the treatment of asthma. |
| Q80252475 | Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan |
Search more.